Delivery Order SPE2DB20D1051-SPE2DB25FD9LT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,287.63 to AmerisourceBergen Drug Corp for Dexcom G7 sensors on September 15, 2025, with completion expected by September 16, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be fulfilled from the contractor's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,891.14 to AmerisourceBergen Drug Corp for Dexcom G7 sensors. The contract, which became effective on June 18, 2025, with an ultimate completion date of June 20, 2025, represents a firm fixed price procurement with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order under its existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,163.54 to AmerisourceBergen Drug Corp for Dexcom G7 continuous glucose monitoring sensors. This firm fixed price contract, awarded on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was made on a non-set-aside, competitive basis and will be performed at...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dexcom G7 sensors, with a ceiling value of $1,375.76. This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $1,023.62 firm fixed-price delivery order for Dexcom G7 sensors, with an ultimate completion date of September 5, 2025. This competitively awarded contract, issued on September 4, 2025, represents a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,031.20 to AmerisourceBergen Drug Corp for Dexcom G7 sensors. This firm fixed-price contract, awarded on August 20, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The award carries no set-aside designation and will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,135.84 to AmerisourceBergen Drug Corp for Dexcom G7 sensors on August 25, 2025, with completion scheduled for August 26, 2025. The contract utilizes firm fixed pricing and was awarded without a set-aside designation through open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor specializing in pharmaceutical products...
- The Defense Logistics Agency has awarded a delivery order valued at $1,694.39 to AmerisourceBergen Drug Corp for Dexcom G7 sensors. This firm fixed price, competitively awarded contract was issued on September 22, 2025, with an ultimate completion date of September 23, 2025. The delivery will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,031.32 to AmerisourceBergen Drug Corp for Dexcom G7 sensors on September 22, 2025, with completion expected by September 23, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The delivery order will be performed at the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,474.88 to AmerisourceBergen Drug Corp for the supply of Dexcom G7 sensors. This firm fixed price, non-competitive delivery order was issued on August 8, 2025, with an ultimate completion date of August 11, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's substantial role as a federal medical supply provider,...
- SPE2DB20D1051Indefinite Delivery Contract
- SPE2DB20D1051-SPE2DB25FD9LTDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,901.57 to AmerisourceBergen Drug Corp for Dexcom G7 sensors on September 15, 2025, with completion targeted for September 16, 2025. This firm fixed price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award utilized no set-aside designation, indicating it was competitively awarded. Performance will occur at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the DLA's Medical Supply Chain. The Dexcom G7 sensors—continuous glucose monitoring devices—support diabetes management across Department of Defense health programs. This delivery order exemplifies the contractor's extensive portfolio of pharmaceutical and medical device distributions, which demonstrates its capability to fulfill federal medical supply requirements through open competition across a wide range of therapeutic domains including specialty medications, vaccines, and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/15/25 |